A Novel Intermediate Alemtuzumab Schedule Optimizes the Incidences of Mixed Chimerism and Acute GVHD in Patients With HLH and XLP Undergoing Allogeneic HCT
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2012.11.433
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2013
Authors
Publisher
Elsevier BV